PTGX - Protagonist Therapeutics, Inc.... | Finranks

12.08.2026

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis and other inflammatory disorders, with phase 2b study initiation planned for Q1 2027.

11.08.2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

07.08.2026

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

05.08.2026

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to a loss of $0.55 per share a year ago.

04.08.2026

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
PTGX	Goldman	Buy	undefined >> $186	August 10th 2026

Пресс-релизы

04.08.2026

Protagonist Therapeutics, Inc. (PTGX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Protagonist Therapeutics Reports Granting of Inducement Awards

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Protagonist Therapeutics Reports Granting of Inducement Awards

Search stocks

Protagonist Therapeutics, Inc. (PTGX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Protagonist Therapeutics Reports Granting of Inducement Awards

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Protagonist Therapeutics Reports Granting of Inducement Awards